Request a market read
Market overview · Central Asia

Uzbekistan: a faster route in.

One of Central Asia's largest markets, growing fast, with registration review times cut sharply in November 2025.

Population

38.2 million (1 Jan 2026)

Pharmaceutical turnover 2025

about USD 2bn, up 18%

Medicine imports 2025

about USD 2bn

Registration review

60–120 days by category

38.2mpeople (2026)
+18%pharmaceutical turnover growth, 2025
60 daysreview for the lowest-risk category, down from 150
120 daysreview for higher-risk categories
The market

Growing, and still import-led.

Fast growth

Pharmaceutical turnover reached about USD 2bn in 2025, up 18% on 2024.

Import-led

Medicine imports were about USD 2bn in 2025. The government is pushing local production to reduce them.

Generics favoured

Generics get a shortened registration period under the November 2025 reform.

Registration

Review times by safety category.

Review timeBefore Nov 2025
Lowest-risk category60 days150 days
Category 290 days—
Higher-risk categories120 days—
GenericsShortened registration period—

Official review times. Real timelines add questions. Registrations are always held in your name.

Our view

Move early, while the clock is short.

File while it's fast

Short review times reward manufacturers who are ready now.

Lead with generics

The shortened route makes well-priced generics the natural first wave.

Plan for local production

Policy favours local manufacturing over time. Enter with that in mind.

Request a market read for Uzbekistan.

Send us your portfolio. We reply within one working day.

UK · WhatsApp
+44 7466 253544
Kazakhstan · WhatsApp
+7 708 692 2409
WhatsApp